08:18 AM EDT, 07/08/2024 (MT Newswires) -- HilleVax ( HLVX ) said on Monday that the phase 2 study of its experimental vaccine, HIL-214, didn't meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis in infants about five months of age.

The company didn't also observe any clinical benefit across secondary goals.

The company said it plans to discontinue further development of HIL-214 in infants and is exploring the potential for continued development of HIL-214 and HIL-216, HilleVax's ( HLVX ) Phase 1 ready vaccine candidate, in adults.

Shares of HilleVax ( HLVX ) fell 90% in recent premarket trading.

Price: 1.40, Change: -12.66, Percent Change: -90.05